CLAZ.F Stock Overview
A clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Claritas Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.0001 |
52 Week High | CA$0.0002 |
52 Week Low | CA$0.000001 |
Beta | 0 |
11 Month Change | 9,900.00% |
3 Month Change | n/a |
1 Year Change | 9,900.00% |
33 Year Change | -99.92% |
5 Year Change | -99.99% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
CLAZ.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 900.0% | 1.6% | 2.2% |
1Y | 9,900.0% | 9.9% | 31.6% |
Return vs Industry: CLAZ.F exceeded the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: CLAZ.F exceeded the US Market which returned 31.7% over the past year.
Price Volatility
CLAZ.F volatility | |
---|---|
CLAZ.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLAZ.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CLAZ.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Bob Farrell | claritaspharma.com |
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.
Claritas Pharmaceuticals, Inc. Fundamentals Summary
CLAZ.F fundamental statistics | |
---|---|
Market cap | US$675.85k |
Earnings (TTM) | US$1.81m |
Revenue (TTM) | n/a |
0.0x
P/E Ratio0.0x
P/S RatioIs CLAZ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLAZ.F income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | -US$1.80m |
Earnings | US$1.81m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did CLAZ.F perform over the long term?
See historical performance and comparison